{"id":"adalimumab-subcutaneous-injection","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Injection site reactions"},{"rate":"7-10%","effect":"Upper respiratory tract infections"},{"rate":"5-8%","effect":"Headache"},{"rate":"0.1-0.5%","effect":"Tuberculosis reactivation"},{"rate":"1-3%","effect":"Opportunistic infections"},{"rate":null,"effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF-α is a key pro-inflammatory cytokine that drives inflammation in autoimmune and inflammatory diseases. By blocking TNF-α, adalimumab suppresses the inflammatory cascade, reducing immune cell activation and tissue damage. This mechanism is effective across multiple inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, and psoriasis.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:35.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Psoriasis"},{"name":"Ankylosing spondylitis"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT06016517","phase":"","title":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-03-15","conditions":"Arthritis, Rheumatoid","enrollment":18},{"nctId":"NCT06100744","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-08","conditions":"Juvenile Psoriatic Arthritis","enrollment":40},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT07344428","phase":"NA","title":"Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-02-01","conditions":"Crohn's Disease；Mucosal Healing；Dietary Intervention","enrollment":185},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT06528431","phase":"PHASE4","title":"Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-12-19","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT01895764","phase":"PHASE4","title":"Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2013-03-20","conditions":"Ankylosing Spondylitis","enrollment":110},{"nctId":"NCT06180382","phase":"PHASE4","title":"Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-10-31","conditions":"Crohn's Disease","enrollment":220},{"nctId":"NCT05394805","phase":"","title":"A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-06-29","conditions":"Crohn's Disease","enrollment":156},{"nctId":"NCT02632175","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Ulcerative Colitis","enrollment":59},{"nctId":"NCT06257875","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-03-23","conditions":"Ulcerative Colitis","enrollment":156},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT07151937","phase":"PHASE2","title":"A Study of LAD191 in Adults With Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2025-09","conditions":"Hidradenitis Suppurativa","enrollment":200},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT07140666","phase":"","title":"Analysis of Influence Factors on Osteopenia in Different Treatment of Psoriasis","status":"COMPLETED","sponsor":"Chongli Yu","startDate":"2022-08-01","conditions":"Psoriasis","enrollment":100},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06729463","phase":"NA","title":"IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"South Valley University","startDate":"2024-12-01","conditions":"Psoriasis, Psoriatic Arthritis","enrollment":50},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT07013838","phase":"PHASE4","title":"The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-06-15","conditions":"Takayasu Arteritis (TAK)","enrollment":50},{"nctId":"NCT05414201","phase":"PHASE4","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Non-infectious Intermediate Posterior- or Pan-uveitis","enrollment":87},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT06310837","phase":"NA","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-03-27","conditions":"Uveitis","enrollment":128},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT03816397","phase":"PHASE4","title":"Adalimumab in JIA-associated Uveitis Stopping Trial","status":"COMPLETED","sponsor":"Nisha Acharya","startDate":"2020-03-15","conditions":"Uveitis, JIA","enrollment":87},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT05884242","phase":"PHASE1","title":"A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-22","conditions":"Healthy","enrollment":20},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT02706704","phase":"PHASE2","title":"Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis","status":"RECRUITING","sponsor":"American University of Beirut Medical Center","startDate":"2016-02","conditions":"Uveitis, Non-Infectious Uveitis","enrollment":32},{"nctId":"NCT06833112","phase":"PHASE4","title":"Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2025-02","conditions":"Ankylosing Spondylitis","enrollment":10},{"nctId":"NCT02852694","phase":"PHASE4","title":"Reduce Risk for Crohn's Disease Patients","status":"COMPLETED","sponsor":"PIBD-Net","startDate":"2017-02-28","conditions":"Crohn's Disease","enrollment":192},{"nctId":"NCT05090124","phase":"NA","title":"Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-11-04","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT03737708","phase":"PHASE4","title":"A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2019-02-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":21},{"nctId":"NCT06242652","phase":"PHASE2","title":"A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-03-19","conditions":"Ankylosing Spondylitis","enrollment":250},{"nctId":"NCT06527534","phase":"PHASE4","title":"Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"Universita di Verona","startDate":"2024-07-15","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT06333210","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2023-12-25","conditions":"Axial Spondyloarthritis","enrollment":421},{"nctId":"NCT04230213","phase":"PHASE3","title":"A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-13","conditions":"Rheumatoid Arthritis","enrollment":455},{"nctId":"NCT05073315","phase":"PHASE3","title":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-10-04","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT04360785","phase":"NA","title":"Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-11-11","conditions":"Spondyloarthritis","enrollment":124},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT02764762","phase":"PHASE4","title":"Triple Combination Therapy in High Risk Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-18","conditions":"Crohn Disease","enrollment":55},{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT02994836","phase":"PHASE4","title":"GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2017-04-21","conditions":"Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis","enrollment":139},{"nctId":"NCT05720221","phase":"","title":"Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-07-15","conditions":"IBD","enrollment":100},{"nctId":"NCT05683626","phase":"","title":"Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-12-15","conditions":"Uveitis","enrollment":40},{"nctId":"NCT05683054","phase":"PHASE4","title":"A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-08-11","conditions":"Psoriasis","enrollment":19},{"nctId":"NCT05172817","phase":"PHASE2, PHASE3","title":"Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients","status":"UNKNOWN","sponsor":"Institute for Developing Science and Health Initiatives, Bangladesh","startDate":"2021-06-02","conditions":"Pharmacokinetics, Safety, Efficacy","enrollment":200},{"nctId":"NCT03357939","phase":"PHASE1","title":"Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-01-12","conditions":"Immune System Disorder","enrollment":220},{"nctId":"NCT04200833","phase":"","title":"Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-03-01","conditions":"JIA Associated Uveitis","enrollment":10},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT02472912","phase":"PHASE1","title":"Adalimumab PK Bioequivalence Study to EU and US Sourced Humira","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-12","conditions":"Healthy Volunteers","enrollment":270},{"nctId":"NCT04705844","phase":"PHASE3","title":"Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)","status":"WITHDRAWN","sponsor":"Alachua Government Services, Inc.","startDate":"2021-09","conditions":"Mild to Moderate COVID-19","enrollment":""},{"nctId":"NCT03955861","phase":"","title":"Ultrasound Enthesitis Response in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2019-02-14","conditions":"Psoriatic Arthritis, Psoriasis, Enthesitis","enrollment":80},{"nctId":"NCT01971970","phase":"","title":"Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-10","conditions":"Inflammatory Bowel Diseases","enrollment":45},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT01373151","phase":"PHASE2","title":"Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT04171414","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-09-09","conditions":"Rheumatoid Arthritis","enrollment":62},{"nctId":"NCT03789292","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-11-26","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT02395055","phase":"PHASE1","title":"Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-06","conditions":"Healthy","enrollment":94},{"nctId":"NCT02471118","phase":"PHASE2","title":"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","status":"COMPLETED","sponsor":"CARE ARTHRITIS LTD.","startDate":"2015-03","conditions":"Osteoarthritis, Knee","enrollment":62},{"nctId":"NCT00837434","phase":"PHASE4","title":"Anti-TNF Agents for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT03607903","phase":"PHASE1, PHASE2","title":"Adalimumab Microneedles in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-07-11","conditions":"Pain, Injection Site","enrollment":24},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02207231","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-26","conditions":"Psoriasis","enrollment":837},{"nctId":"NCT02207244","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-03","conditions":"Psoriasis","enrollment":992},{"nctId":"NCT03823391","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-03-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":48},{"nctId":"NCT01166282","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Enthesitis Related Arthritis (ERA)","enrollment":46},{"nctId":"NCT01148225","phase":"PHASE3","title":"A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2010-11-23","conditions":"Uveitis","enrollment":424},{"nctId":"NCT01468233","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":326},{"nctId":"NCT01468207","phase":"PHASE3","title":"Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-11","conditions":"Hidradenitis Suppurativa (HS)","enrollment":307},{"nctId":"NCT01124838","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":261},{"nctId":"NCT01138657","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":239},{"nctId":"NCT00573794","phase":"PHASE3","title":"Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-11-28","conditions":"Ulcerative Colitis","enrollment":592},{"nctId":"NCT01064856","phase":"PHASE3","title":"Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Peripheral Spondyloarthritis","enrollment":165},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT02746380","phase":"PHASE3","title":"A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-04-13","conditions":"Arthritis, Rheumatoid","enrollment":383},{"nctId":"NCT03927352","phase":"PHASE3","title":"The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2019-09-05","conditions":"Psoriasis","enrollment":330},{"nctId":"NCT03917628","phase":"PHASE1","title":"Pharmacokinetics and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"Sinocelltech Ltd.","startDate":"2019-05-29","conditions":"Healthy","enrollment":146},{"nctId":"NCT02065557","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Ulcerative Colitis","enrollment":101},{"nctId":"NCT00311246","phase":"PHASE2","title":"Trial of Adalimumab in Progressive Sarcoidosis","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2006-04","conditions":"Sarcoidosis","enrollment":11},{"nctId":"NCT02808975","phase":"PHASE4","title":"Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-18","conditions":"Hidradenitis Suppurativa (HS)","enrollment":206},{"nctId":"NCT02904902","phase":"PHASE3","title":"Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-06","conditions":"Hidradenitis Suppurativa","enrollment":15},{"nctId":"NCT04018599","phase":"PHASE1","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2019-07-15","conditions":"Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis","enrollment":216},{"nctId":"NCT02497469","phase":"PHASE3","title":"An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-06-29","conditions":"Colitis, Ulcerative","enrollment":771},{"nctId":"NCT00690846","phase":"PHASE2","title":"Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2007-07","conditions":"Pyoderma Gangrenosum","enrollment":""},{"nctId":"NCT01387815","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-08-16","conditions":"Psoriasis","enrollment":662},{"nctId":"NCT02750800","phase":"","title":"Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-07","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":427},{"nctId":"NCT02413047","phase":"NA","title":"Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator","status":"TERMINATED","sponsor":"Indiana University","startDate":"2015-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adalimumab subcutaneous injection","genericName":"Adalimumab subcutaneous injection","companyName":"Biocad","companyId":"biocad","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}